Anti-Envelope protein E Biosimilar – Anti-Dengue virus mAb – Research Grade from ProteoGenix; catalogue PX-TA1622; research use only.
Know who made it. See the evidence. Buy through one marketplace.
The Anti-Envelope protein E Biosimilar – Anti-Dengue virus mAb – Research Grade is a novel antibody that has been developed for the treatment of Dengue virus infection. Dengue virus is a mosquito-borne virus that causes Dengue fever, a potentially life-threatening illness that affects millions of people worldwide every year. The envelope protein E of Dengue virus is a major therapeutic target for the development of antiviral drugs and vaccines. In this article, we will discuss the structure, activity, and potential applications of this biosimilar antibody.
The Anti-Envelope protein E Biosimilar is a monoclonal antibody (mAb) that specifically binds to the envelope protein E of Dengue virus. It is a recombinant protein that is produced in a mammalian cell expression system. The antibody has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains. The heavy chains are composed of four constant regions (Fc) and one variable region (VH), while the light chains have two constant regions (CL) and one variable region (VL). The variable regions of the antibody are responsible for binding to the envelope protein E of Dengue virus.
The Anti-Envelope protein E Biosimilar exerts its activity by binding to the envelope protein E of Dengue virus and inhibiting its function. The envelope protein E is responsible for the attachment of the virus to host cells and the fusion of the viral and cellular membranes, which is essential for viral entry and replication. By binding to the envelope protein E, the biosimilar antibody prevents the virus from entering and infecting host cells, thereby inhibiting viral replication and spread.
In addition to its direct antiviral activity, the Anti-Envelope protein E Biosimilar also has an immunomodulatory effect. It can enhance the immune response against Dengue virus by promoting the production of neutralizing antibodies and activating immune cells such as B cells and natural killer cells. This dual mechanism of action makes the biosimilar antibody a promising therapeutic agent for the treatment of Dengue virus infection.
The Anti-Envelope protein E Biosimilar has potential applications in both the treatment and prevention of Dengue virus infection. As a therapeutic agent, it can be used to treat patients with severe Dengue fever, reducing the severity and duration of the illness and preventing complications such as Dengue hemorrhagic fever and Dengue shock syndrome. It can also be used as a prophylactic treatment for individuals at high risk of Dengue virus infection, such as travelers to endemic areas.
Furthermore, the biosimilar antibody can also be used in the development of diagnostic assays for the detection of Dengue virus. Its specific binding to the envelope protein E makes it a valuable tool for the detection and quantification of the virus in patient samples, aiding in the diagnosis and monitoring of Dengue virus infection.
In conclusion, the Anti-Envelope protein E Biosimilar – Anti-Dengue virus mAb – Research Grade is a promising antibody with potential applications in the treatment, prevention, and diagnosis of Dengue virus infection. Its unique structure and dual mechanism of action make it a valuable therapeutic agent for this life-threatening disease. Further research and clinical trials are needed to fully evaluate the efficacy and safety of this biosimilar antibody, but it holds great promise in the fight against Dengue virus.
ProteoGenix catalogue number PX-TA1622. For research use only.
Target: Envelope protein E Biosimilar – Anti-Dengue virus mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer pH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Envelope protein E Biosimilar – Anti-Dengue virus mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
